The Portuguese generic medicines market: What's next?

被引:5
|
作者
Nunes, Alexandre Morais [1 ,2 ]
Ferreira, Diogo Cunha [2 ]
de Matos, Andreia [1 ]
Juliao, Rui Miranda [1 ]
机构
[1] Univ Lisbon, Inst Super Ciencias Sociais & Polit, CAPP, R Almerindo Lessa, P-1300663 Lisbon, Portugal
[2] Univ Lisbon, Inst Super Tecn, CERIS, Av Rovisco Pais, P-1049001 Lisbon, Portugal
关键词
Generics; Portugal; Economic crisis; Broadening use of generics; DRUGS; HEALTH; PERCEPTIONS;
D O I
10.1016/j.healthpol.2020.02.014
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Brand-name medicines have dominated the Portuguese market for several decades with unquestionable exclusivity. This resulted particularly from the absence of a requirement of prescriptions by international non-proprietary name. To promote the enhancement of both efficiency and sustainability in the health system, the Portuguese government introduced the generics in Portugal by the 90 s. However, only in the first decade of the 21st century were some policies implemented to increase their market share. Although some expectations were created, the use of generics has increased moderately during that period, in which policies to promote them were consolidated by imposing the austerity principles in the midst of the economic and social crisis. This study analyses the main policy measures already implemented as well as the incentives created for the replacement of brand-name medicines with generics. In addition, the present study also makes some recommendations to promote a broader and better use of generics in Portugal. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:397 / 403
页数:7
相关论文
共 50 条
  • [1] A POLICY ANALYSIS OF THE PORTUGUESE GENERIC MEDICINES MARKET
    Simoens, S.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A240 - A240
  • [2] The generic medicines market in Europe
    Simoens, Steven
    [J]. EJHP PRACTICE, 2009, 15 (02): : 67 - 69
  • [3] WHAT HAPPENS TO ORIGINATOR MEDICINES WHEN (GENERIC) FOLLOWERS ENTER THE PUBLIC MARKET
    Habl, C. A.
    Leopold, C.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A443 - A444
  • [4] What's in a name? Brand name confusion and generic medicines
    Carney, Shane L.
    Gazarian, Madlen
    Denholm, Justin T.
    Reith, David M.
    Penhall, Robert K.
    Jenkins, Christine R.
    Wilhelm, Kay A.
    Komesaroff, Paul A.
    Osborn, Mary M.
    Day, Richard O.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2011, 195 (11-12) : 650 - 651
  • [5] Analysis of French generic medicines retail market: why the use of generic medicines is limited
    Dylst, Pieter
    Vulto, Arnold
    Simoens, Steven
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 795 - 803
  • [6] National Medicines Policy 2.0- what's changed and what's next?
    McLachlan, Andrew J.
    Aslani, Parisa
    [J]. AUSTRALIAN PRESCRIBER, 2023, 46 (04) : 72 - 74
  • [7] Analysis of the Korean generic medicine market: Factors affecting the market share of generic medicines
    Kim, Dong-Sook
    Shin, Jihye
    Chung, Jusun
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (02): : 433 - 441
  • [8] Generic medicines: Solutions for a sustainable drug market?
    Dylst P.
    Vulto A.
    Godman B.
    Simoens S.
    [J]. Applied Health Economics and Health Policy, 2013, 11 (5) : 437 - 443
  • [9] Generic medicines entry into the Malaysian pharmaceutical market
    Fatokun, Omotayo
    Ibrahim, Mohamed Izham Mohamed
    Hassali, Mohamed Azmi
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2016, 5 (04): : 180 - 181
  • [10] Generic medicines supply in France: analysis of the market
    Taboulet, F
    Haramburu, F
    Latry, P
    [J]. REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2003, 51 (04): : 415 - 425